KCM
CLDX icon

Kynam Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Kynam Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-246,400
Closed -$2.48M – 39
2022
Q2 		$2.48M Buy
+246,400
New +$7.16M 0.63% 21

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Kynam Capital Management's CLDX Position: Q2 2026 in Review

Kynam Capital Management reduced its Celldex Therapeutics (CLDX) stake by 8.9% in Q2 2026, selling an estimated $16.7M and leaving 5,322,908 shares worth $198M. The position accounts for 10.95% of the portfolio, ranked #1.

Kynam Capital Management first reported a position in CLDX in Q4 2021 and has held it in 19 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Kynam Capital Management held 5,322,908 shares of Celldex Therapeutics worth $198M as of Q2 2026.
  • Kynam Capital Management sold 517,659 Celldex Therapeutics shares in Q2 2026, an estimated $16.7M.
  • Celldex Therapeutics made up 10.95% of Kynam Capital Management's portfolio in Q2 2026, its #1 holding.
  • Kynam Capital Management first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.